Paper Details

  1. Home
  2. Paper Details

Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.

Author: GoldblumOrin, PaulCarle, PuigLluis, ThaçiDiamant, UnnebrinkKristina, van de KerkhofPeter

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adalimumab treatment resulted in significant improvements in skin, nails, quality of life, pain, and pruritus for patients with moderate to severe psoriasis, regardless of their baseline psoriatic arthritis status.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Adalimumab is a fully human anti-TNF monoclonal antibody with demonstrated efficacy and safety in patients with moderate to severe psoriasis and psoriatic arthritis (PsA). OBJECTIVE: This study examined the effect of PsA on adalimumab treatment response in patients from the Phase IIIb B...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1684/ejd.2012.1863

データ提供：米国国立医学図書館（NLM）

The Impact of Psoriatic Arthritis on Adalimumab Treatment

This study investigates the influence of psoriatic arthritis (PsA) on the effectiveness of adalimumab, a widely used treatment for psoriasis and PsA. Analyzing data from a large clinical trial, the researchers explore how PsA may affect adalimumab's efficacy and the response of various markers of disease burden.

Adalimumab's Effectiveness across Psoriasis and PsA

The research demonstrates that adalimumab effectively treats both psoriasis and PsA, achieving significant improvements in a variety of disease markers.

Navigating the Challenges of Psoriasis and PsA

Imagine psoriasis as a stubborn desert sandstorm, causing discomfort and disrupting normal life. Psoriatic arthritis adds another layer of complexity to the situation, with joint pain and stiffness making everyday activities even more challenging. This study provides valuable insights into the efficacy of adalimumab in managing both psoriasis and PsA, offering hope for improved patient outcomes.

Dr.Camel's Conclusion

This study underscores the effectiveness of adalimumab in treating both psoriasis and PsA. The findings offer valuable information for clinicians and patients seeking effective treatment options for these challenging conditions.
Date :
  1. Date Completed 2013-06-19
  2. Date Revised 2016-06-29
Further Info :

Pubmed ID

23178916

DOI: Digital Object Identifier

10.1684/ejd.2012.1863

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.